CC-486 and Venetoclax for Acute Myeloid Leukemia

Primary Objective

To determine the maximum tolerated or recommended dose of CC-486 in combination with venetoclax

Study category: Cancer

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Type of Study

Treatment

Locations

Lone Tree Medical Center
University of Colorado Hospital

Principal Investigator
Daniel Pollyea,  MD, MS

Daniel Pollyea, MD, MS

Study ID

Protocol Number: 20-1319

More information available at ClinicalTrials.gov: NCT05287568

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers